Navigation Links
Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
Date:10/22/2008

ilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS" in our annual report on Form 10-K for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on February 29, 2008. The forward-looking statements in this press release and on the related conference call are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

The Company will hold a conference call with research analysts at 8 a.m. Eastern Daylight Time today. The purpose of the call is to review the financial results of the Company for the 2008 third quarter and first nine months. Interested investors and others may listen to the call live or on a delayed basis through the Internet webcast, which may be accessed by visiting the Company's Internet Web site at http://www.wyeth.com and clicking on the "Investor Relations" hyperlink.

Also, for recent announcements and additional information, including product sales information, please refer to the Company's Internet Web site.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Wyeth Wins Philadelphia Diet Drug Trial Involving Claim of PPH
2. Wyeth Announces Increase in Common Stock Dividend
3. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
4. Wyeth Sets Webcast And Conference Call for 2008 Third Quarter Earnings
5. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
6. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
7. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
8. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
9. Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
10. Wyeth Declares Common and Preferred Stock Dividends
11. Wyeth Pharmaceuticals Announces Organizational Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... BOSTON , Feb. 27, 2015   PureTech ... identifying, inventing and commercializing disruptive products and technologies in ... Christopher Viehbacher , former CEO and Member of the ... Directors.  "It,s has been a pleasure ... very excited that we will be working together more ...
(Date:2/26/2015)... WOODBRIDGE, N.J. , Feb. 26, 2015 ... and its affiliated companies, Wilentz, Goldman & ... a trade secrets lawsuit against Genewiz Inc. in excess ... obtained and utilized GenScript,s trade secrets, and that it ... court entered an order denying motions for judgment notwithstanding ...
(Date:2/26/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... commercializes proprietary technologies and products for advanced microarray diagnostics, ... fiscal first quarter ended December  31, 2014. All figures ... unless otherwise stated. "During the quarter ... existing customers and add to our sales pipeline," said ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015   Regulus ... biopharmaceutical company leading the discovery and development of innovative ... Xanthopoulos , Ph.D., President and Chief Executive Officer of ... and Company 35 th Annual Healthcare Conference on ... conference is being held at the Boston Marriott Copley ...
Breaking Biology Technology:Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... , , WEST CHESTER and ... a leading global medical device company in the orthopaedic trauma, spine, ... (Nasdaq: KNSY ), a leading developer and manufacturer of ... developed from Kensey Nash,s unique extracellular matrix (ECM) technology. , ...
... Ltd,(SIX: ARPN) announced today its financial results for the six months ending,30 ... - Regulatory setback for intravenous iclaprim in cSSSI in ... - Company restructuring completed, , Cash and financial ... CFO Harry Welten, MBA, commented: "Our cost-saving measures have been,implemented, ...
... , , CLEVELAND, Aug. 19 It,s ... field using technology in a "meaningful" way. While it,s clear ... the exact role technology will play to help achieve that goal. Proven ... or administrative, at the right time, content management will clearly play an ...
Cached Biology Technology:Synthes and Kensey Nash Announce Strategic Agreement for Extracellular Matrix Products 2Synthes and Kensey Nash Announce Strategic Agreement for Extracellular Matrix Products 3Synthes and Kensey Nash Announce Strategic Agreement for Extracellular Matrix Products 4Synthes and Kensey Nash Announce Strategic Agreement for Extracellular Matrix Products 5Arpida Reports Interim Results For Six Months to 30 June 2009 2Healthcare Continues to Use OnBase in 'Meaningful' Ways 2Healthcare Continues to Use OnBase in 'Meaningful' Ways 3Healthcare Continues to Use OnBase in 'Meaningful' Ways 4
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
(Date:2/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Conference on January 29 th at 10:30 a.m. ... of NXT-ID will present and host a live Q&A ... and its full suite of biometric technologies. Investors can ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... have all but disappearedwere home to dozens of species of ... hundreds of species of flowers, and herds of roaming bison. ... by the University of Colorado Boulder has gotten a peek ... once called the tallgrass prairie home: the diverse assortment of ...
... AMHERST, Mass. Usually indigestion is a bad thing, ... Robert Vass at the University of Massachusetts Amherst recently ... partial degradation of a DNA replication protein is required ... one of the most highly controlled biological processes in ...
... Institute of Biotechnology have used the power of ... atomic movements. The research is helping to chart ... "glycomes" - the entire complement of carbohydrates within ... new understanding of these vital biomolecules which play ...
Cached Biology News:CU-Boulder-led team gets first look at diverse life below rare tallgrass prairies 2Biochemists find incomplete protein digestion is a useful thing for some bacteria 2Gaming technology unravels 1 of the most complex entities in nature 2Gaming technology unravels 1 of the most complex entities in nature 3
... your microarray data using Asuragens bioinformatics ... need from consultation to extensive data ... date methods. Utilize our expertise in ... Service or from your own microarray ...
... This CLS number is a new ... Cornings product number. If showing no ... old Sigma-Aldrich number (Z71,517-4) or contact ... cap polystyrene (expanded surface, easy grip) ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Material: cap ...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,704-5) ... assistance. ...
Biology Products: